Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104204591 | 10420459 | 1 | I | 2014 | 20140514 | 20140701 | 20140701 | PER | 1000067350 | FOREST | 65.00 | YR | F | N | 0.00000 | 20140612 | N | MD | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104204591 | 10420459 | 1 | PS | LINZESS | LINACLOTIDE | 1 | ORAL | 145 MCG ( 145 MCG, 1 IN 1 D), ORAL | N | D | 202811 | 145 | UG | 1X | |||||
| 104204591 | 10420459 | 3 | C | MIRALAX ( POLYETHYLENE GLYCOL) ( POLYETHYLENE GLYCOL) | 2 | 0 | |||||||||||||
| 104204591 | 10420459 | 5 | C | ABILIFY ( ARIPIPRAZOLE) (ARIPIPRAZOLE) | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 104204591 | 10420459 | 1 | Constipation |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 104204591 | 10420459 | Anorectal disorder | |
| 104204591 | 10420459 | Diarrhoea | |
| 104204591 | 10420459 | Faecal incontinence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 104204591 | 10420459 | HP |
| 104204591 | 10420459 | CR |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 104204591 | 10420459 | 1 | 201404 | 201405 | 0 |